Welcome to our dedicated page for Cellectis news (Ticker: CLLS), a resource for investors and traders seeking the latest updates and insights on Cellectis stock.
About Cellectis
Cellectis (NASDAQ: CLLS) is a clinical-stage biopharmaceutical company at the forefront of gene-editing technologies, dedicated to developing innovative cancer immunotherapies and other therapeutic solutions. Leveraging over 18 years of expertise in genome engineering, Cellectis has established itself as a pioneer in the field, utilizing its proprietary TALEN® (Transcription Activator-Like Effector Nucleases) technology and PulseAgile electroporation system to create precise, next-generation therapies. These tools enable the company to harness the immune system's power to target and eliminate cancer cells effectively.
Core Focus: Allogeneic CAR-T and Gene-Edited HSPCs
Cellectis specializes in developing allogeneic Chimeric Antigen Receptor T-cells (UCART) for immuno-oncology applications. Unlike traditional autologous CAR-T therapies, which require harvesting and engineering a patient’s own cells, Cellectis’s allogeneic approach uses gene-edited donor cells. This innovation offers scalability, reduced manufacturing costs, and faster availability, making it a game-changer in cancer treatment. Additionally, the company is advancing gene-edited hematopoietic stem and progenitor cells (HSPCs) for therapeutic indications beyond oncology, showcasing its versatility in genome editing.
Proprietary Technologies
Cellectis’s competitive edge lies in its proprietary technologies:
- TALEN® Technology: A precise and versatile gene-editing tool that enables targeted modifications to DNA, ensuring high specificity and minimal off-target effects.
- PulseAgile Electroporation System: A cutting-edge delivery platform that enhances the efficiency of introducing genetic material into cells.
These technologies form the backbone of Cellectis’s product pipeline, enabling the development of innovative therapies that address unmet medical needs.
Market Position and Industry Context
Cellectis operates within the rapidly growing fields of immuno-oncology and precision medicine. The global demand for effective cancer therapies continues to rise, driven by advancements in biotechnology and an increasing understanding of the immune system's role in combating diseases. As a clinical-stage company, Cellectis focuses on research and development, with a pipeline of promising product candidates undergoing rigorous clinical trials. However, this stage also presents challenges, including regulatory approvals, high R&D costs, and competition from other biotech firms specializing in gene editing and CAR-T therapies.
Competitive Landscape
Key competitors in the gene-editing and CAR-T therapy space include CRISPR Therapeutics, Editas Medicine, and Intellia Therapeutics. Cellectis differentiates itself through its allogeneic approach, which offers significant advantages in scalability and cost-effectiveness. By addressing the limitations of autologous therapies, such as manufacturing complexity and patient-specific variability, Cellectis positions itself as a leader in next-generation cancer immunotherapies.
Challenges and Opportunities
While Cellectis’s innovative approach holds immense promise, the company faces several challenges. These include navigating a complex regulatory environment, managing high development costs, and competing in a crowded market. However, the potential rewards are substantial, with successful therapies offering transformative benefits for patients and significant market opportunities. The company’s focus on leveraging proprietary technologies and addressing unmet medical needs positions it well for long-term success.
Conclusion
Cellectis is a trailblazer in the biopharmaceutical industry, combining cutting-edge gene-editing technologies with a commitment to innovation in cancer immunotherapy and beyond. By leveraging its proprietary TALEN® technology and allogeneic approach, the company aims to revolutionize the treatment landscape, offering scalable, cost-effective solutions to some of the most pressing medical challenges. As a clinical-stage entity, Cellectis represents a high-risk, high-reward opportunity within the dynamic biotechnology sector.
Cellectis announced its total number of shares as of November 30, 2022, standing at 45,579,410, with total voting rights totaling 51,646,286.
Cellectis, listed on both Nasdaq Global Market (ticker: CLLS) and Euronext Growth (ticker: ALCLS), focuses on gene-editing therapies targeting cancers and blood disorders. Its proprietary technologies include TALEN® and PulseAgile.
The company aims to address unmet medical needs through innovative cell and gene therapies, notably for acute myeloid leukemia and multiple myeloma.
Cellectis S.A. (CLLS) announced updated clinical data from its BALLI-01 and AMELI-01 studies at the ASH 2022 meeting. In the BALLI-01 trial, UCART22 showed anti-tumor activity in 60% of patients at dose level 3 (DL3) after FCA lymphodepletion, with one patient maintaining a durable MRD-negative complete response for over 12 months. Meanwhile, AMELI-01 demonstrated a 25% meaningful response rate at dose level 2 (DL2), including a patient achieving sustained MRD-negative status. The company is now enrolling patients in both studies with in-house manufactured product candidates.
Cellectis, a clinical-stage biotechnology company focused on gene editing, will host a live webcast on December 13, 2022, at 7:30 AM ET. The event will review clinical data from the AMELI-01 study evaluating UCART123 and include a company update. Presentations by the management team will precede a Q&A session. Interested participants can register for the webcast on Cellectis’ website. The company, listed on NASDAQ (CLLS) and Euronext Growth (ALCLS), emphasizes its commitment to developing life-saving therapies using its innovative gene-editing platform.
Cellectis, a clinical-stage biotechnology company, announced the presentation of preclinical data on TALEN®-edited smart CAR T-cells at the SITC 37th Annual Meeting. The data, focusing on targeting solid tumors, includes two key presentations about MUC-1 CAR T-cells and T-cell engineering strategies that improve anti-tumor efficacy while minimizing toxicity. The innovative approaches address challenges faced by CAR T-cell therapies in solid tumors, particularly triple-negative breast cancer. The presentations are available on Cellectis' website following the event.
Cellectis (ticker: CLLS), a clinical-stage biotechnology company, has published a manuscript in Frontiers Bioengineering and Biotechnology showcasing the effectiveness of a multiplex gene editing approach using TALEN® and TALE base editing technologies. This combination enables efficient double gene knock-outs of TRAC and CD52, essential for allogeneic CAR T-cell therapies, with minimal by-products. The study achieved up to 80% and 75% phenotypic knock-outs respectively, paving the way for safer and more controllable gene editing applications in therapeutic settings.
Cellectis reported as of October 31, 2022, a total of 45,567,810 shares in its capital and 51,634,701 voting rights. This biotechnology company specializes in gene-editing and focuses on developing CAR-T immunotherapies for various cancers. Cellectis employs its proprietary TALEN® technology and PulseAgile system to advance treatments for acute myeloid leukemia and other serious conditions. The company continues to expand its portfolio while maintaining a commitment to address unmet medical needs.
Cellectis reported its Q3 2022 results, highlighting a cash position of $103 million as of September 30, 2022. Revenues fell to $9 million, down from $53 million in the same period last year, primarily due to decreased milestone payments. R&D expenses were $85 million, reflecting notable cost management. The net loss attributable to shareholders decreased to $79 million or $1.74 per share, compared to $89 million in the prior year. Additionally, several clinical trials progressed, including UCART123's upcoming oral presentation at the ASH 2022 Annual Meeting.
Cellectis has announced two abstracts accepted for presentation at the 64th ASH Annual Meeting from December 10-13, 2022. The AMELI-01 study evaluating UCART123 in patients with relapsed/refractory acute myeloid leukemia (r/r AML) will showcase preliminary data, highlighting improved activity with alemtuzumab. Additionally, a poster on UCARTCS1 will present preclinical data demonstrating anti-tumor activity in multiple myeloma. Cellectis aims to address unmet medical needs using its gene-editing platform to develop innovative therapies.
Cellectis, a clinical-stage biotechnology company, is set to announce its Q3 2022 financial results on November 3, 2022, after the US market closes. This will be followed by a conference call on November 4, 2022, at 8:00 AM EDT to discuss the results and provide a business update. Cellectis focuses on developing innovative gene-editing therapies using TALEN® technology and is pioneering off-the-shelf CAR-T immunotherapies. The company is listed on Nasdaq under the symbol CLLS.
FAQ
What is the current stock price of Cellectis (CLLS)?
What is the market cap of Cellectis (CLLS)?
What does Cellectis specialize in?
How does Cellectis differentiate from competitors?
What are Cellectis’s proprietary technologies?
What challenges does Cellectis face?
What is the significance of allogeneic CAR-T therapies?
What market does Cellectis target?
Who are Cellectis’s main competitors?
What stage of development is Cellectis in?
